Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Acro Biomedical (ACBM) EBT Margin (2017 - 2022)

Acro Biomedical has reported EBT Margin over the past 6 years, most recently at 1092.97% for Q4 2022.

  • Quarterly results put EBT Margin at 1092.97% for Q4 2022, down 146547.0% from a year ago — trailing twelve months through Sep 2023 was 3534.45% (down 245144.0% YoY), and the annual figure for FY2022 was 2410.24%, down 227517.0%.
  • EBT Margin for Q4 2022 was 1092.97% at Acro Biomedical, up from 1316.18% in the prior quarter.
  • Over the last five years, EBT Margin for ACBM hit a ceiling of 7903.87% in Q3 2019 and a floor of 1316.18% in Q1 2022.
  • Median EBT Margin over the past 5 years was 1.01% (2018), compared with a mean of 469.47%.
  • Biggest five-year swings in EBT Margin: soared 789733bps in 2019 and later tumbled -146547bps in 2022.
  • Acro Biomedical's EBT Margin stood at 7.01% in 2018, then plummeted by -459bps to 39.2% in 2019, then soared by 130bps to 11.79% in 2020, then skyrocketed by 3059bps to 372.5% in 2021, then tumbled by -393bps to 1092.97% in 2022.
  • The last three reported values for EBT Margin were 1092.97% (Q4 2022), 1316.18% (Q1 2022), and 372.5% (Q4 2021) per Business Quant data.